Technical Analysis for ELYM - Eliem Therapeutics, Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Parabolic Rise | Strength | 6.97% | |
| Upper Bollinger Band Walk | Strength | 6.97% | |
| Multiple of Ten Bearish | Other | 6.97% | |
| Wide Bands | Range Expansion | 6.97% | |
| Upper Bollinger Band Touch | Strength | 6.97% | |
| New 52 Week Closing High | Bullish | -2.25% | |
| 180 Bullish Setup | Bullish Swing Setup | -2.25% | |
| Parabolic Rise | Strength | -2.25% | |
| Upper Bollinger Band Walk | Strength | -2.25% | |
| Multiple of Ten Bullish | Other | -2.25% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 1 hour ago |
| Up 5% | about 1 hour ago |
| Up 3% | about 2 hours ago |
| Up 2% | about 2 hours ago |
| Up 1% | about 2 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/13/2024
Eliem Therapeutics, Inc Description
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The company's lead clinical-stage candidates include ETX-810, a novel palmitoylethanolamide prodrug that is in Phase IIa clinical trials for the treatment of diabetic peripheral neuropathic pain and pain associated with lumbosacral radiculopathy; and ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures. Its lead preclinical program includes Kv7.2/3 potassium channel opener for epilepsy and pain; and novel analog of 2,3- benzodiazepine for the treatment of generalized anxiety disorder. The company was incorporated in 2018 and is headquartered in Redmond, Washington.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pain Neuroscience Disorders Chronic Pain Epilepsy Major Depressive Disorder Neurophysiology Neuropathic Pain Treatment Of Major Depressive Disorder Peripheral Neuropathy Gabaa Receptor Positive Allosteric Modulators Perimenopausal Depression
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.55 |
| 52 Week Low | 2.34 |
| Average Volume | 1,069,693 |
| 200-Day Moving Average | 2.99 |
| 50-Day Moving Average | 3.96 |
| 20-Day Moving Average | 5.79 |
| 10-Day Moving Average | 7.38 |
| Average True Range | 1.09 |
| RSI (14) | 69.97 |
| ADX | 50.3 |
| +DI | 45.89 |
| -DI | 3.81 |
| Chandelier Exit (Long, 3 ATRs) | 8.29 |
| Chandelier Exit (Short, 3 ATRs) | 5.91 |
| Upper Bollinger Bands | 10.42 |
| Lower Bollinger Band | 1.15 |
| Percent B (%b) | 0.88 |
| BandWidth | 160.09 |
| MACD Line | 1.64 |
| MACD Signal Line | 1.12 |
| MACD Histogram | 0.5223 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.70 | ||||
| Resistance 3 (R3) | 11.95 | 11.41 | 11.31 | ||
| Resistance 2 (R2) | 11.41 | 10.80 | 11.28 | 11.17 | |
| Resistance 1 (R1) | 10.36 | 10.42 | 10.09 | 10.11 | 11.04 |
| Pivot Point | 9.82 | 9.82 | 9.68 | 9.69 | 9.82 |
| Support 1 (S1) | 8.77 | 9.21 | 8.50 | 8.53 | 7.60 |
| Support 2 (S2) | 8.23 | 8.83 | 8.10 | 7.47 | |
| Support 3 (S3) | 7.18 | 8.23 | 7.33 | ||
| Support 4 (S4) | 6.94 |
